Quantib has been acquired by RadNet
Quantib has been acquired by RadNet
ROTTERDAM, January 24, 2022 – Our portfolio company Quantib has been acquired by RadNet, Inc. (NASDQ: RDNT), a US leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 350 owned and operated outpatient imaging centers. Quantib is a leading radiology artificial intelligence (“AI”) company focusing on clinical solutions for prostate cancer, breast cancer and neurodegeneration.
Founded in 2012 as spin-off from the Erasmus Medical Centre and based in Rotterdam, Quantib has multiple AI-based solutions with both CE mark and FDA 510(k) clearance, including Quantib Prostate for analysis of prostate MR images and Quantib ND to quantify brain abnormalities on MRI. Quantib has customers in more than 20 countries worldwide, including the United States. Holland Capital and InnovationQuarter joined the company in 2017 as investors. With the investment, Quantib has expanded her product portfolio and accelerated commercial growth.
Arthur Post Uiterweer, CEO of Quantib noted, “We are thrilled to join the RadNet family. Quantib aims to enable more accurate and efficient clinical decision-making for 10 million patients by 2030. Being part of RadNet enables us to take a major step towards this goal. Our products, that are already received very well by customers, will see a tremendous boost in performance over the coming years to the benefit of all of our rapidly expanding global user base.”
Dr. Howard Berger, Chairman and CEO of RadNet, noted, “We remain convinced that artificial intelligence will have a transforming impact on diagnostic imaging and the field of radiology. We are very pleased to expand our portfolio of AI software into other cancer screening domains. With the addition of Quantib, we will now have effective screening solutions for the three most prevalent cancers.
Jan Frens van Giessel, partner Holland Capital, “We are proud that we have been able to assist Quantib in the past 5 years in realizing its growth ambitions. With the acquisition of RadNet, Quantib can take the next step forward and make an even greater contribution to improving and optimizing (international) healthcare”.
The full management including Arthur Post Uiterweer (CEO), Jorrit Glastra (CTO) and Quirine van Voorst (COO) will stay onboard with Quantib and are thrilled to continue to lead the company as it enters this exciting new phase.
Quantib’s AI radiology solutions enable faster and more accurate diagnosis by quickly identifying abnormalities, supporting adequate and timely patient care. Using state-of-the-art artificial intelligence techniques, Quantib’s software advances the diagnostic pathway by providing FDA-cleared and CE marked solutions related to neurodegeneration and prostate cancer. All solutions are deployed through Quantib’s AI Node platform enabling seamless workflow integration and rapid regulatory clearance of future products. Quantib was founded in 2012 as a spin-off of Erasmus Medical Centre in Rotterdam, the Netherlands. It has a rapidly expanding team of 35 employees and has customers across 20+ countries globally. www.quantib.com.
RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 350 owned and/or operated outpatient imaging centers. RadNet’s markets include California, Maryland, Delaware, New Jersey, New York, Florida and Arizona. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 9,000 employees. www.radnet.com.
About Holland Capital
Over the past 40 years, Holland Capital has responsibly and successfully invested in over more than 150 SME-companies. With a clear investment strategy Holland Capital is active in the attractive growth markets of Healthcare and Technology. Holland Capital’s experienced and committed investment team aims to establish an open, sustainable, and professional relationship with the companies they invest in, with the common goal of achieving growth. Holland Capital is backed by a broad network of successful healthcare entrepreneurs in the relevant growth markets. www.hollandcapital.nl